empagliflozin effect in polycystic ovarian syndrom

? Comparative study of the effect of metformin and empagliflozin on cardiometabolic, anthropometric and hormonal factors in women with polycystic ovarian syndrom

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220822055771N1

Enrollment

Registered

2023-01-31

Start date

2022-11-22

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: The people of this group are given empagliflozin 10 mg tablets (ABIDI company) once a day for three months. Intervention 2: Control group: The people of this group

Eligibility

Sex/Gender

Female

Age

15 Years to 55 Years

Inclusion criteria

Inclusion criteria: women between 15-55 years old polycystic ovarian syndrom

Exclusion criteria

Exclusion criteria: Glomerular filtration rate<30 pregnant liver disease diabet mellitus urinary tract infection chronic disease on hypertention treatment

Design outcomes

Primary

Measure	Time frame
Weight. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: Digital scale.;Body mass index. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: Meter and scale.;Waist circumfernce. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: Measuring tape.;Fasting blood sugar. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: spectrophotometry.;Hba1c. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: HPLC.;Total testestrone. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: ECLIA.;17-oh progesterone. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: ELISA.;Dehydroepiandrosterone. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: ELISA.;AST (aspartate aminotransferase). Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: ELISA.;Alanine transaminase(ALT). Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: ELISA.;C-reactive protein (CRP). Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: ELISA.;Triglycerides. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: spectrophotometry.;LDL (low-density lipoprotein). Timepoint: before the start of the intervention and three months after the start of the intervent	—

Measure

Time frame

Weight. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: Digital scale.;Body mass index. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: Meter and scale.;Waist circumfernce. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: Measuring tape.;Fasting blood sugar. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: spectrophotometry.;Hba1c. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: HPLC.;Total testestrone. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: ECLIA.;17-oh progesterone. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: ELISA.;Dehydroepiandrosterone. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: ELISA.;AST (aspartate aminotransferase). Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: ELISA.;Alanine transaminase(ALT). Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: ELISA.;C-reactive protein (CRP). Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: ELISA.;Triglycerides. Timepoint: before the start of the intervention and three months after the start of the intervention. Method of measurement: spectrophotometry.;LDL (low-density lipoprotein). Timepoint: before the start of the intervention and three months after the start of the intervent

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Khosravi

Shahre-kord University of Medical Sciences

St-khosravi.s@skums.ac.ir+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026